uniQure (NASDAQ:QURE) Given Consensus Recommendation of “Moderate Buy” by Analysts

uniQure (NASDAQ:QURE) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $17.00.

A number of research analysts have recently weighed in on QURE shares. Royal Bank of Canada cut their price target on uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a report on Thursday, October 17th. Raymond James reissued an “outperform” rating and set a $20.00 price target on shares of uniQure in a research report on Thursday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of uniQure in a research note on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 target price on shares of uniQure in a research report on Wednesday, November 6th.

Institutional Trading of uniQure

A number of hedge funds have recently made changes to their positions in QURE. abrdn plc increased its holdings in uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after acquiring an additional 752,889 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of uniQure by 133.1% during the 1st quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after acquiring an additional 350,291 shares in the last quarter. FMR LLC lifted its stake in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Finally, Ikarian Capital LLC boosted its holdings in shares of uniQure by 198.1% in the 1st quarter. Ikarian Capital LLC now owns 469,133 shares of the biotechnology company’s stock valued at $2,439,000 after buying an additional 311,768 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Price Performance

QURE stock opened at $5.82 on Wednesday. uniQure has a twelve month low of $3.73 and a twelve month high of $11.35. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $283.67 million, a P/E ratio of -1.17 and a beta of 0.90. The business has a 50 day simple moving average of $5.91 and a 200-day simple moving average of $5.93.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities analysts anticipate that uniQure will post -3.81 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.